spacer
home > ict > autumn 2019 > learning to fish in data lakes
PUBLICATIONS
International Clinical Trials

Learning to Fish in Data Lakes





Today, clinical operations teams are drowning in data but starving for information, at a time of intense pressure to speed up clinical trials and restrain costs (1). The massive volumes of data generated during clinical trials are woefully inadequate at helping stakeholders spot risk factors and bottlenecks that can disrupt cycle times and budgets, primarily due to the inefficient ways in which operational data are captured and analysed, often relying on outdated methods such as Excel. Excel was not designed to collect and analyse clinical trial data as it lacks project management capability, yet its extensive use persists (2-3).

Having technology that can automate or assist in the timely monitoring of trials is a huge improvement over the current status quo of manual methods such as spreadsheets, which are cumbersome and erroneous, not to mention they only provide a dated view of trial performance.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the author


Craig Morgan is responsible for directing the global marketing strategy and team for the Oracle Health Sciences suite of study startup applications, working with sponsors, CROs, medical device manufacturers, and sites to reduce cycle times and improve collaboration and oversight in clinical trials. He is a technology and life science management professional with over 15 years’ experience in the application of informatics and bioinformatics to drug discovery, and eClinical technology associated with starting clinical trials. Craig holds degrees in Analytical Chemistry, Information Systems, and Business Administration and is a certified Project Manager with the Project Management Institute.
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Approval marks the first all-oral, once-daily, fixed-duration Bruton’s tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement